Lexaria Bioscience Corp’s ( NASDAQ:LEXX/ CSE:LXX;) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules and drugs.
The Company’s technology can be applied to many different drugs and other active ingredients such as vitamins in oral formats including tablets, capsules, oral suspensions – and even foods, beverages and topical preparations.
DehydraTECH is one of the world’s newest technologies specifically designed to improve the efficacy of orally administered bioactive molecules, including anti-viral drugs, nicotine, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and other molecules.
Companies with operations in over 100 countries around the world are examining DehydraTECH for possible use in the smokeless tobacco-derived nicotine industry, in the health and wellness industry, and more. Lexaria is investigating whether its technology might be useful for more effectively delivering drugs in the fight against certain viruses including SARS-CoV-2 that causes COVID-19. . Lexaria operates a federally-licensed in-house research laboratory and is building a robust intellectual property portfolio with 18 patents granted internationally as of Fall, 2020, and roughly 60 patents pending worldwide.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Bio-absorption into blood circulation increases by roughly 100% – 500%, more than doubling the quantity of drug delivered into the bloodstream. Bio-absorption into brain tissue, in repeated animal studies, increases by 200% to 1,900%, opening possibilities for improved drug delivery for central nervous system disorders such as Alzheimer’s and Parkinson’s.
Eliminates the strong tastes/odors of many bitter lipophilic compounds, without the need for unwanted sugar or sweeteners
In animal studies, delivery into the bloodstream after oral gavage has been measured in as little as 2 minutes. Effects of different API’s are commonly felt within minutes compared to conventional oral dosage forms which may require up to 60-120 minutes for onset to begin.
Initial testing measuring liver metabolites indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to “first pass” liver exposure reducing liver biotransformation and potentially mitigating unwanted side effects.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. DehydraTECH is protected by 18 granted patents internationally as of Fall, 2020 and roughly 60 additional pending patents for use with a broad range of bioactive molecules, including but not limited to: